Injury of the brain is a major cause of death and morbidity after the prolonged seizures termed status epilepticus (SE). Studies in rodents have demonstrated that cyclooxygenase 2 (COX2) activation by ischemia and SE generally contributes to neuronal injury, but multiple downstream COX2 signaling pathways, and our data, suggest that the mechanisms promoting and opposing brain injury are complex. Cell culture medium:  500 ml DMEM high glucose medium, 50 ml FBS (10% heat-inactivated), 5 ml Pen Strept, 15 ml 50 mg/ml  Geneticin Procedure: 1. Grow cells: Cells were grown over a week in T-175 flasks and split when appropriate to reach the final volume of 40-50 T-175 flasks necessary for screening. 2. Harvest cells: 1. Aspirate medium from T-175 flasks, rinse with HBSS without Ca-Mg. 2. Add 3 ml /flask Versene (EDTA, 0.2 mg/ml) (BioWhittaker Cat# 17-711E) 3. Tap flasks vigorously 4. Add 10 ml/flask HBSS (+Ca+Mg) and combine the cells in 4 centrifuge tubes (50ml) 5. Centrifuge cells at 800g for 8 min 6. Discard supernant 7. Resuspend cells in about 100 ml HBSS(+Ca+Mg) 8. Count cell number 3. Cell density optimization Make dilutions of PGE2 in HBSS to arrive at testing concentrations of PGE2. Make dilutions of cells to arrive at testing concentrations of cells. Add 1 ul of d2-conjugate (1:9 in HBSS) and incubate at RT for 10 - 40 min Add 2 ul of anti-cAMP Europium conjugate (1:18), centrifuge plate and incubate at RT for 20min to 2 hr Read FRET signal using Envision (100us delay) Analyze data and calculate the EC50s at differen cell density Choose cell density for screening (EC50 of PGE2 is 1 - 3 nM) 4. Screening Step 1:  make 250 ml of cells (for 40 1536-well plates), add 250 ul of 10 mM Rolipram Step 2: dispense 4 ul of cells to column 3 - 46 Step 3:  dispense 1 ul of HBSS to column 3 - 4 Step 4: add 0.1 ul of 1 mM compound (final compound concentration: 20 uM) using Pin-tool (Beckman NX) Step 5: add 1 ul of 6 uM PGE2 to PGE2 control wells (final 1 uM) Step 6: add 1 ul of 120 uM Forsklin to forsklin contrl wells (final 20 uM) Step 7: dispense 1 ul of d2-conjugate (1:9) to column 4 Step 8: make mixture of d2-conjugate and PGE2: Step 9: dispense 2 ul of d2-conjugate and PGE2 mixture to column 5 - 46 step 10: shake plates well, centrifuge plates at 1500g for 10min, incubate at RT for around 10mins (no longer that 20 min) Step 11: dispense 2 ul of anti-cAMP Europium conjugate (1: 18 dilution in lysis buffer) to column 3 - 46 Step 12: shake plates well,  centrifuge plates at 1500g for 10 min and incubate at RT for 10 min. Put plates to 4C refregrator before reading Step 13: Read plates uisng Envision with Twister II robot. Run 5 plates/batch from refrigerator. 5.  Data analysis: Data analysis: 1. FRET signals are expressed as FRET ratios: FRET ratio = F665 nm / F615 nm * 10000 F665 nm: Fluorescence counts at 665 nm emission (units: cps) F620 nm: Fluorescence counts at 615 nm emission (units: cps) 2. Assay data are analyzed using BioAssay software from CambridgeSoft. Percentage of inhibition is calculated with the following equation based on normalized data from each plate. Normalized FRET signal = ((FRET compound well - FRET blank(compound added)) / ((FRET compound well - FRET background) (no compound added)) % of activity = (Normalized FRET signal from compound well / average normalized FRET signal from control wells) * 100 % of inhibition = 100 - % of activity Where FRET compound well is the FRET ratio from a well with a test compound, FRET background is an average FRET ratio from wells with cells, Anti-cAMP-Eu and HBSS buffer only; FRET control is an average FRET ratio from wells containing 0.3 nM PGE2 that defines maximum FRET signal. Percent induction is then calculated based on a comparison with wells containing 1 uM PGE2: % induction = (Pct Inhibition Compound / Pct Inhibition 1 uM PGE2) * 100 Actives are compounds that are positive (>50% induction of cAMP) in assay 1 but negative (<30% induction of cAMP signal) in assays 2-5. Compounds found to be active are assigned a PUBCHEM_ACTIVITY_SCORE of 100, those found to be inactive are assigned a PUBCHEM_ACTVIITY_SCORE of 0.
bao:BAO_0000541 "940" ; # "is counter assay of" -> "940"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0000154 bao:BAO_0000543 ; # "has orthogonal assay design" -> "orthogonal assay design"
bao:BAO_0000205 bao:BAO_0000219 ; # "has assay format" -> "cell-based format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000284 ; # "has participant" -> "G protein coupled receptor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0000650 ; # "is bioassay type of" -> "cAMP redistribution assay"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000212 bao:BAO_0000129 ; # "has assay method" -> "immunoassay"
bao:BAO_0000207 bao:BAO_0000002 ; # "has detection method" -> "homogeneous time resolved fluorescence"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Modulators of the prostaglandin E2 receptor subtype EP2" ; # "screening campaign name" -> "Modulators of the prostaglandin E2 receptor subtype EP2"
bao:BAO_0002853 "Modulators of the EP2 prostaglandin EP2 receptor - Primary Counterscreens" ; # "has assay title" -> "Modulators of the EP2 prostaglandin EP2 receptor - Primary Counterscreens"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "10 minute" ; # "has incubation time value" -> "10 minute"
bao:BAO_0002857 "PGE2 1 micromolar" ; # "has signal direction" -> "PGE2 1 micromolar"
bao:BAO_0000740 bao:BAO_0000156 ; # "has assay control" -> "high signal control"
bao:BAO_0002857 "Forskolin 20 micromolar" ; # "has signal direction" -> "Forskolin 20 micromolar"
bao:BAO_0000740 bao:BAO_0000168 ; # "has assay control" -> "low signal control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Raymond Dingledine" ; # "material entity assay provider" -> "Raymond Dingledine" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000373 ; # "has assay phase characteristic" -> "heterogeneous phase"
bao:BAO_0002000 bao:BAO_0001013 ; # "has measured entity" -> "Rolipram" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35222> ; # "has role" -> "inhibitor"
bao:BA0_0090012 "Prostaglandin E2 receptor EP2 subtype" ; # "has participant" -> "Prostaglandin E2 receptor EP2 subtype"
bao:BAO_0002004 bao:BAO_0002703 ; # "has cell line" -> "C6"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P43116" ; # "uniprot ID" -> "P43116"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10% heat inactivated fetal bovine serum" ; # "material entity culture serum" -> "10% heat inactivated fetal bovine serum" || bao:BAO_0003102 bao:BAO_0002596 ; # "has role" -> "culture serum"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"DMEM high glucose medium, 10% heat-inactivated FBS, Pen Strept, 50 mg/ml Geneticin\"" ; # "material entity culture medium" -> ""DMEM high glucose medium, 10% heat-inactivated FBS, Pen Strept, 50 mg/ml Geneticin"" || bao:BAO_0003102 bao:BAO_0000114 ; # "has role" -> "culture medium"
bao:BAO_0002922 "HBSS with Ca and Mg" ; # "has assay medium" -> "HBSS with Ca and Mg"
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
bao:BAO_0000502 "\"Europium Eu3+ cryptate-labeled anti-cAMP, HTRF fluorophore donor, Cisbio\"" ; # "antibody" -> ""Europium Eu3+ cryptate-labeled anti-cAMP, HTRF fluorophore donor, Cisbio""
bao:BA0_0090012 bao:BAO_0000875 ; # "has participant" -> "Cyclic adenosine monophosphate"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000937 ; # "has assay kit" -> "HTRF cAMP Detection Kit"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000881 ; # "has manufacturer" -> "Cisbio" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0000648 bao:BAO_0000733 ; # "compound library" -> "MLSMR library"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "330 nanometer" ; # "has excitation wavelength value" -> "330 nanometer"
bao:BAO_0002918 "620 nanometer" ; # "has emission wavelength value" -> "620 nanometer"
bao:BAO_0002918 "665 nanometer" ; # "has emission wavelength value" -> "665 nanometer"
bao:BAO_0000337 bao:BAO_0000200 ; # "has percent response" -> "percent activation"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5" ; # "PubChem TID" -> "5"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "25" ; # "has concentration value" -> "25"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "3" ; # "has repetition point-number" -> "3"
bao:BAO_0000196 bao:BAO_0000537 ; # "has mode of action" -> "allosteric binding"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
bao:BAO_0001070 bao:BAO_0001064 ; # "has alternate target assay" -> "alternate target assay"
bao:BAO_0002000 bao:BAO_0001012 ; # "has measured entity" -> "Ro 20-1724"
bao:BAO_0002000 bao:BAO_0000950 ; # "has measured entity" -> "Isoproterenol" || bao:BAO_0003102 bao:BAO_00020138 ; # "has role" -> "potentiator"
bao:BA0_0090012 "Beta-2 adrenergic receptor" ; # "has participant" -> "Beta-2 adrenergic receptor"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0001230> ; # "has cell line" -> "293 cell"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P07550" ; # "uniprot ID" -> "P07550"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing the human beta-2 adrenergic receptor" ; # "DNA construct" -> "Expressing the human beta-2 adrenergic receptor"
bao:BAO_0003105 "adrenoceptor beta 2" ; # "has function" -> "adrenoceptor beta 2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "154" ; # "construct gene ID" -> "154"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "4" ; # "PubChem TID" -> "4"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0002000 bao:BAO_0001001 ; # "has measured entity" -> "Prostaglandin E2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BA0_0090012 "Prostaglandin E2 receptor EP4 subtype" ; # "has participant" -> "Prostaglandin E2 receptor EP4 subtype"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P35408" ; # "uniprot ID" -> "P35408"
bao:BAO_0000550 "Expressing the human EP4 prostanoid receptor under control of the CMV promoter" ; # "DNA construct" -> "Expressing the human EP4 prostanoid receptor under control of the CMV promoter"
bao:BAO_0003105 "prostaglandin E receptor 4 (subtype EP4)" ; # "has function" -> "prostaglandin E receptor 4 (subtype EP4)"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5734" ; # "construct gene ID" -> "5734"
bao:BAO_0003105 bao:BAO_00020152 ; # "has function" -> "foreign promoter region"
bao:BAO_0003105 "cytomegalovirus" ; # "has function" -> "cytomegalovirus"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
bao:BAO_0000540 "940" ; # "is confirmatory assay of" -> "940"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000550 "Expressing the human EP2 prostanoid receptor under control of the CMV promoter" ; # "DNA construct" -> "Expressing the human EP2 prostanoid receptor under control of the CMV promoter"
bao:BAO_0003105 "\"prostaglandin E receptor 2 (subtype EP2), 53kDa\"" ; # "has function" -> ""prostaglandin E receptor 2 (subtype EP2), 53kDa""
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5732" ; # "construct gene ID" -> "5732"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1" ; # "PubChem TID" -> "1"
